Pediatric anesthesia & critical care
Justification of empiric methodology to determine dexmedetomidine dose for the TREX study
Authors' conclusion
This current PK analysis from the Italian arm of the TREX study confirms that plasma concentration of dexmedetomidine is predictable using known covariates such as age and size.
Study context
- Population
- Children aged less than 2 years undergoing anaesthesia of 2 hours or longer, receiving dexmedetomidine/remifentanil and low dose sevoflurane (Italian population)162 blood samples
- Participants
- 32 children
Methodological detailssecondary analysis of the TREX randomised trial, population pharmacokinetic modelling, 3-compartment model, allometric scaling and maturation function, Italian interventional arm
- Secondary analysis of the TREX randomised trial
- Population pharmacokinetic modelling
- 3-compartment model
- Allometric scaling and maturation function
- Italian interventional arm
Primary result
As reported in the abstract
Dexmedetomidine plasma concentrations
- Observed plasma concentrations consistent with those predicted by a "universal" model using pooled data from neonates to adults
Further findings
Patient characteristics
- Age, median (IQR), months
- 12 (5.2-15.5)
- Weight, median (IQR), kg
- 9.9 (7.3-10.8)
- Duration of anaesthesia, hours
- 2-6
- Postnatal age, median (IQR), weeks; none born premature
- 39 (38-40)
Original publication
Justification of empiric methodology to determine dexmedetomidine dose for the TREX study. Paediatr Anaesth. Published 17 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →